
Novo Nordisk has come one step closer to getting its obesity drug Wegovy approved in Europe, as the CHMP has recommended is approval.
The EU Commission still needs to authorize the drug, but this is generally seen as a formality once a CHMP recommendation is in place. According to a Novo Nordisk press release, the company expects this to happen within the next two months.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app